IV NAD+ and oral NAD+ precursors (NMN, NR) are fundamentally different interventions with different pharmacokinetics, different acute experiences, and different clinical applications. This page covers the IV form specifically. Read the oral NAD+ page →
COMPOUND PROFILE · PEPPERLEDGER
NAD+ IV (Intravenous NAD+)
NAD+ — nicotinamide adenine dinucleotide — endogenous coenzyme present in every cell
Type
Endogenous coenzyme — same molecule as in every cell; delivered IV for acute systemic elevation that bypasses the oral biosynthesis pathway entirely
IV infusion — typically 500–1000 mg in 250 mL saline, over 2–4 hours. Licensed clinic setting required. Never self-administer IV.
Half-life
NAD+ in plasma: minutes (rapidly consumed by CD38 and distributed). Cellular effects persist 7–14+ days post-infusion.
Most studied use
Longevity reset protocol · Addiction and withdrawal (most clinical data) · Depression and mental health · Post-illness energy restoration
Regulatory status
Not FDA-approved as a drug for any indication · Administered off-label at IV wellness clinics and functional medicine practices globally · No prescription required in most jurisdictions
Human evidence
Moderate — clinical data for addiction/withdrawal, depression, and neurological conditions. Significant real-world clinical use. Longevity application has mechanistic support but no outcomes trial.
Preclinical evidence
Exceptionally strong for NAD+ restoration in aging — one of the most studied molecules in aging biology
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
IV NAD+ vs. oral NMN/NR — this is not just 'stronger NMN'
When you take NMN or NR orally, NAD+ rises gradually over days and weeks as the precursor is absorbed, distributed, and converted to NAD+ inside cells. The rise is modest, sustained, and happens quietly in the background — most people don't feel it acutely. When you receive IV NAD+, you are flooding the bloodstream directly — NAD+ plasma levels spike within minutes of starting the infusion, rapidly distributing to tissues, and users often experience the effects within the infusion itself: a profound shift in energy, mental clarity, and in some cases emotional wellbeing that is qualitatively different from anything oral supplementation produces.
The mechanism for IV NAD+'s acute effects is still being characterized. NAD+ doesn't cross cell membranes as efficiently as its precursors — most cellular NAD+ is synthesized intracellularly from precursors rather than taken up directly. Yet the effects are consistently reported. Current hypothesis: extracellular NAD+ activates purinergic receptors (P2Y and P2X receptors expressed on neurons, immune cells, and other tissues), producing immediate signaling effects independent of intracellular NAD+ metabolism.
The clinical applications where IV NAD+ has the strongest evidence are substance addiction and withdrawal — specifically opioid, alcohol, and stimulant withdrawal programs, where it significantly reduces craving, withdrawal symptom severity, and detoxification time. This is the application with the most accumulated clinical data. The longevity and anti-aging application is mechanistically compelling but lacks comparable clinical outcomes data.
How it works
Direct Systemic NAD+ Elevation
IV NAD+ bypasses the oral bioavailability and intracellular synthesis steps entirely. Plasma NAD+ levels rise within minutes of starting the infusion and peak at infusion end. From plasma, NAD+ distributes to tissues — though the intracellular uptake mechanism remains debated. CD38 (an NAD+-consuming enzyme on red blood cells and immune cells) rapidly consumes a portion of circulating NAD+. The net tissue distribution and persistence above oral precursor-raised levels is an active research question.
Extracellular NAD+ Receptor Signaling
The most compelling explanation for IV NAD+'s acute within-infusion effects is extracellular receptor activation. NAD+ and its metabolite NAADP activate purinergic receptors (P2Y11, P2X receptors) on neurons, immune cells, and other tissues. These extracellular signaling effects — distinct from intracellular NAD+'s role as a metabolic coenzyme — explain the rapid effects that oral precursors cannot replicate. This is an active research frontier: extracellular NAD+ as a signaling molecule.
CD38, Chronic Inflammation, and NAD+ Depletion
CD38 is upregulated by inflammation and is one of the primary drivers of NAD+ depletion in aged and chronically ill tissue. Chronic inflammation dramatically accelerates NAD+ consumption via CD38. IV NAD+ transiently overcomes this CD38-driven depletion by flooding the system with substrate — which explains why chronically ill or stressed individuals often have more dramatic responses to IV NAD+ than already-healthy individuals.
The Infusion Experience — Why It Feels Different
IV NAD+ infusions commonly produce during-infusion effects that no oral supplement produces: nausea or chest tightness if infused too quickly, followed by energy, warmth, and mental clarity as the infusion slows. These effects reflect rapid systemic distribution and extracellular receptor activation in real time. Slowing the infusion rate resolves acute discomfort without stopping the therapeutic effect — standard clinic protocol.
What the research shows
STUDYAntioxidants · 2020
IV NAD+ for opioid, alcohol, and stimulant withdrawal — clinical outcomes
Braidy N et al.
Review of clinical program data including Springfield Wellness Center's long-running IV NAD+ withdrawal program. Significant reduction in withdrawal symptoms, craving, and acute detoxification time across opioid, alcohol, and stimulant withdrawal cases. The application with the most accumulated clinical data for IV NAD+.
Therapeutic potential of NAD-boosting molecules: the in vivo evidence
Rajman L et al.
Comprehensive review of NAD+ biology, age-related decline, and evidence for IV and oral supplementation across aging and disease. Covers the preclinical case (exceptionally strong) and early human evidence for NAD+ restoration. Best single reference for understanding why NAD+ repletion is a longevity strategy.
IV NAD+ has one of the most consistent and enthusiastic communities of any IV treatment — the acute experience is distinctive enough that users describe it in specific, consistent terms regardless of where they received the infusion. Common descriptors: during-infusion nausea and chest tightness (resolved by slowing the drip — expected and universal with first-time infusions), post-infusion clarity and energy described as unlike anything in the oral supplement experience, and the 'reset' description — returning to a baseline not felt in months or years. Quarterly maintenance is the most common longevity protocol; more frequent during illness recovery or high-stress periods. The NAD+ + glutathione IV stack (NAD+ first, glutathione push at the end) is the signature protocol at most longevity clinics.
WHAT THE RESEARCH SHOWS
✓KNOWN
✓IV NAD+ produces immediate systemic NAD+ elevation that no oral precursor replicates — different pharmacokinetics, different experience
✓Clinical data for addiction/withdrawal (opioid, alcohol, stimulant) — significant craving and symptom reduction
✓During-infusion nausea and chest tightness are normal, expected, and resolved by slowing the infusion rate
✓NAD+ declines ~50% between ages 20 and 60 — the longevity rationale is mechanistically sound
?Whether acute extracellular receptor activation is responsible for the within-infusion experience — mechanism not definitively confirmed
?How much intracellular NAD+ actually rises from IV vs. oral precursors at matching doses — measurement challenge
?Optimal frequency and dose for longevity vs. other applications — quarterly is community consensus, not formally established
?Long-term human outcomes data for the longevity application — no healthspan or lifespan RCT exists
?Whether IV NAD+ provides meaningful additive benefit over daily oral NMN/NR in already-supplemented, healthy individuals
AI COACH PREVIEW
I'm getting my first NAD+ IV infusion next week. What should I expect and how do I track it properly?
First infusion: plan for 3–4 hours minimum, and don't schedule anything strenuous after. Start slow — the clinic should begin at a low drip rate. The first 30–60 minutes you may feel nothing or mild warmth. As the infusion rate increases (if they push it), expect: chest tightness, a strong urge to take deep breaths, possible nausea, and flushing. This is normal. Tell the nurse immediately when this happens — they slow the drip, it passes in 5–10 minutes, and you continue. Don't try to push through it; let the nurse pace it. After the infusion: the experience varies significantly. Some people feel nothing immediately and wake up the next morning transformed. Others feel the shift during the infusion. Expect 2–7 days of enhanced energy, clearer thinking, and lighter mood. Track in PepperLedger: infusion date, dose (ask the clinic — should be 500–1000mg), duration, any during-infusion symptoms, post-infusion energy and clarity on day 1/3/7, and how long the benefit lasts before fading back to baseline. That fade point tells you your optimal frequency. For maintenance: if the benefit lasts 10+ days, quarterly is likely sufficient. If it fades in 3–5 days, monthly may be appropriate. Also: if you're doing this at a longevity clinic, ask about adding glutathione at the end — most clinics offer a glutathione push (600–1200mg) as a 15-minute add-on at the conclusion of the NAD+ infusion. The combination is worth it.
CONTINUE IN THE APP
Open PepperLedger to log your NAD+ IV protocol →
Free to join. Log each infusion, track the duration of benefit, and ask the Coach how to optimize your IV protocol frequency.
Free to join · No credit card · 23-day Pro trial included